SCHEMBL3274413

SCHEMBL3274413

Cc1cc(N(Cc2ccccc2)S(=O)(=O)c2ccccc2)ccc1C(=O)N1CCN(c2ccccc2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.56
KMT2A Q03164 3/20 0.55
HPGD P15428 1/20 0.55
HTT P42858 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
HTR1A P08908 1/20 0.49
HTR2A P28223 1/20 0.49
HTR2C P28335 1/20 0.49
HTR7 P34969 1/20 0.49
DRD3 P35462 1/20 0.49
HTR6 P50406 1/20 0.49
CNR2 P34972 1/20 0.49
MCL1 Q07820 3/20 0.48
BCL2L1 Q07817 2/20 0.48
MEN1 O00255 1/20 0.48
USP2 O75604 1/20 0.48
MAPK1 P28482 1/20 0.48
CLEC4M Q9H2X3 1/20 0.47
GAA P10253 1/20 0.47
GPR55 Q9Y2T6 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL302099 0.88 KMT2A (0.54) LMNAKMT2AHPGDHTTSMN1; SMN2
SCHEMBL303307 0.86 LMNA (0.71) LMNAKMT2AHPGDHTTSMN1; SMN2
SCHEMBL303907 0.83 LMNA (0.65) LMNAKMT2AHPGDHTTSMN1; SMN2
SCHEMBL1711093 0.83 LMNA (0.71) LMNAKMT2AHPGDHTTSMN1; SMN2
SCHEMBL302112 0.83 LMNA (0.65) LMNAKMT2AHPGDHTTSMN1; SMN2
SCHEMBL302427 0.80 KMT2A (0.68) LMNAKMT2AHPGDHTTSMN1; SMN2
SCHEMBL1710747 0.79 LMNA (0.59) LMNAKMT2AHPGDHTTSMN1; SMN2
SCHEMBL302243 0.79 LMNA (0.62) LMNAKMT2AHPGDHTTSMN1; SMN2
SCHEMBL1711134 0.79 LMNA (0.63) LMNAKMT2AHPGDHTTSMN1; SMN2
SCHEMBL302271 0.79 LMNA (0.68) LMNAKMT2AHPGDHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP claimed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US claimed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP disclosed
US-8258138-B2 Potassium channel blockers XENTION LIMITED (GB) 2012-09-04 US disclosed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087437-A1 Novel Potassium Channel Blockers KCNB1, KCNJ2, KCNJ11 LMNA 1683/4885KMT2A 777/4885HPGD 3739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.